Risk stratification for PML in patients treated with Tysabri

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Risk stratification for PML in patients treated with Tysabri

Post by MSUK »

Image

Abstract

Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS).

Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV).

We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Tysabri (Antegren, Natalizumab)”